Clinical trial
Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL
NCT00379574 · Asan Medical Center, Other · Completed
Key facts
| NCT number | NCT00379574 |
|---|---|
| Title | Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL |
| Official title | A Phase I/II Study of Bortezomib Plus CHOP Every 2 Weeks in Patients With Advanced Stage Diffuse Large B-cell Lymphomas |
| Lead sponsor | Asan Medical Center, Other |
| Collaborators | Janssen Korea, Ltd., Korea Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Large-Cell, Diffuse, B-Cell |
| Intervention type | Drug |
| Interventions | Bortezomib, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, Lenograstim |
| Enrollment | 49 |
| Start date | Sep 1, 2006 |
| Primary completion | Jan 1, 2011 |
| Completion | Jan 1, 2011 |
| First posted | Sep 22, 2006 |
| Last update posted | Mar 15, 2013 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: